

Supplemental Tables for:  
 Prediction of benefit from checkpoint inhibitors in mismatch repair deficient metastatic colorectal cancer: role of tumor infiltrating lymphocytes  
 Fotios Loupakis et al.

**Table S1 – Supplementary Materials. Patients' characteristics at diagnosis of metastatic disease**

			RESPONSE*			PFS	OS
Characteristic		Total = 80 N (%)	CR or PR to ICI N = 48 (%)	SD or PD to ICI N = 31 (%)	<i>P</i> -value <sup>§</sup>	HR, (95% CI), <i>P</i> -value <sup>§</sup>	HR (95% CI), <i>P</i> -value <sup>§</sup>
<i>Gender</i>	a. Female	35 (43.8)	23 (47.9)	12 (38.7)	0.491	0.47 (0.20-1.14), 0.095	0.56 (0.21-1.48), 0.242
	b. Male	45 (56.2)	25 (52.1)	19 (61.3)			
<i>Age</i>	Median (range)	60 (17-85)	60 (22-85)	61 (17-80)	-	-	-
<i>Age (70 years cut-off)</i>	a. >70	22 (27.5)	14 (29.2)	8 (25.8)	0.802	0.35 (0.10-1.17), 0.087	0.28 (0.06-1.20), 0.087
	b. ≤70	58 (72.5)	34 (70.8)	23 (74.2)			
<i>Presentation of mets</i>	a. Synchronous	41 (51.3)	25 (52.1)	16 (51.6)	1.000	1.50 (0.67-3.40), 0.328	2.15 (0.82-5.68), 0.121
	b. Metachronous	39 (48.7)	23 (47.9)	15 (48.4)			
<i>N° of metastatic sites</i>	a. Multiple	31 (38.7)	22 (45.8)	9 (29.0)	0.162	0.63	0.80

	b. Single	49 (61.3)	26 (54.2)	22 (71.0)		(0.27-1.48), <i>0.286</i>	(0.31-2.04), <i>0.642</i>
<i>Liver involvement</i>	a. Yes	25 (31.3)	16 (33.3)	9 (29.0)	0.806	0.88 (0.36-2.13),	1.68 (0.68-4.18),
	b. No	55 (68.7)	32 (66.7)	22 (71.0)		<i>0.777</i> <i>0.265</i>	
<i>Lung involvement</i>	a. Yes	7 (8.8)	6 (12.5)	1 (3.2)	0.236	0.71 (0.16-3.06),	1.08 (0.25-4.67),
	b. No	73 (91.2)	42 (87.5)	30 (96.8)		<i>0.643</i> <i>0.921</i>	
<i>Peritoneal involvement</i>	a. Yes	30 (37.5)	14 (29.2)	15 (48.4)	0.099	1.19 (0.53-2.67),	0.93 (0.37-2.38),
	b. No	50 (62.5)	34 (70.8)	16 (51.6)		<i>0.679</i> <i>0.893</i>	

\* 1 patient not evaluable for response to immune checkpoint inhibition (ICI)

§ All comparisons made for variable a vs b. Fisher's exact test was adopted for Response analyses, Log-rank test for PFS and OS analyses. Significant p-values in bold.

CR=complete response; PR=partial response; SD=stable disease; PD=progression disease

**Table S2 – Supplementary Materials. Immune checkpoint inhibition (ICI) best overall response (BOR)**

<b>BOR to ICI</b>	<b>Total = 80 N (%)</b>	
<i>Complete Response (CR)</i>	6 (7.5)	ORR* = 48 (60)
<i>Partial Response (PR)</i>	42 (52.5)	
<i>Stable Disease (SD)</i>	19 (23.8)	DCR** = 67 (83.8)
<i>Progression Disease (PD)</i>	12 (15.0)	
<i>Not evaluable</i>	1	

\* ORR=overall response rate

\*\* DCR=disease control rate

**Table S3 – Supplementary Materials.** Exploratory cohort

<b>TMB</b>		<b>Total = 20</b>
All patients	Median (range)	68.6 (11 – 227.9)
<i>Super responder</i> /N=13	Median (range)	78.6 (11 – 227.9)
<i>Clearly refractory</i> /N=7	Median (range)	50.4 (23.6 – 101.8)
<b>TILs</b>		<b>Total = 20</b>
All patients	Median (range)	4 (0.9 – 9.2)
<i>Super responder</i> /N=13	Median (range)	4 (0.9 – 9.2)
<i>Clearly refractory</i> /N=7	Median (range)	2.1 (0.9 – 7.6)

**Table S4 – Supplementary Materials.** TILs density in the whole cohort

TILs density		Total = 80
High ( $\geq 2$ )	N (%)	52 (65.0)
Low ( $< 2$ )	N (%)	28 (35.0)
All patients	Median (range)	3.0 (0.2 – 47.4)
Responder/N=48*	Median (range)	3.6 (0.2 – 47.4)
Not responder/N=31*	Median (range)	1.8 (0.4 – 8.6)

\* 1 patient not evaluable for response